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Administration of Exogenous 
Corticotropin-Releasing Hormone 
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Summary: ACTH has been used extensively for treat- 
ment of massive infantile spasms (MIS) and other intrac- 
table seizures. The mechanisms by which ACTH exerts 
anticonvulsant effects are unknown. ACTH is a neuro- 
peptide with both endocrine and neuromodulatory prop- 
erties; its efficacy against MIS could derive from intrinsic 
anticonvulsant properties or from hormonal effects, ei- 
ther directly or through glucocorticoids. We tested 
ACTH activity against exogenous corticotropin-releasing 
hormone (CRH)-induced seizures in the infant rat model. 
CRH was administered into the cerebral ventricles of 85 
infant rats aged 5-13 days. ACTH was used either 20-60 
min before CRH administration or “chronically” (pre- 
treatment with four doses of ACTH every 6 h, before 
CRH administration). In a separate group of rat pups, we 
measured plasma corticosterone to ascertain ACTH 
Since the 1958 report of Sore1 and Dusaucy- 
Bauloye (1958) regarding the efficacy of ACTH for 
treatment of massive infantile spasms (MIS), the 
peptide has been used extensively for treatment of 
this entity, as  well as  for other intractable seizures. 
The time course of ACTH effects, the “all-or- 
none” response of MIS, and the lasting effect on 
the seizures once ACTH therapy is discontinued, 
single out ACTH from conventional antiepileptic 
drugs (AEDs) (Hrachovy et al., 1983; Aicardi, 1986; 
Hrachovy and Frost, 1989; Snead, 1989; Snead and 
Simonato, 1991). 
We hypothesized that the anticonvulsant effects 
of ACTH derived from its hormonal action, i.e., a 
negative-feedback effect on corticotropin-releasing 
hormone (CRH) synthesis o r  activity (Baram, 
1993). We previously showed that CRH is a potent 
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availability. Administration of CRH, an age-specific en- 
dogenous convulsant, resulted in a prolonged series of 
seizures after 2- to 55-min latency. There was no differ- 
ence in latency between controls (9.5 2 1.2 min) and 
ACTH-treated rats (12.4 & 2.8 min for combined acute 
and chronic groups). CRH-induced seizure duration (88.2 
& 9 vs. 74.7 2 9.4 min) and severity of seizures was also 
unchanged by ACTH treatment. ACTH reached the cir- 
culation and caused significant increase in plasma gluco- 
corticoids. ACTH does not block the convulsant action of 
exogenous CRH in infant rats. An alternative mechanism 
for the anticonvulsant effect of ACTH may be suppres- 
sion of synthesis and secretion of an endogenous convul- 
sant, i.e., CRH. Key Words: Epilepsy-Infantile 
spasms-Corticotropin-releasing hormone-Infants- 
Epilepsy models-Anticonvulsant effects-Rats. 
and rapid convulsant in infant rats (Baram and 
Shultz, 1991; Baram et al., 1992). The present study 
was designed to investigate the effect of ACTH, 
given acutely or “chronically,” on seizures induced 
by CRH in neonatal and infant rats. 
METHODS 
Animals and surgical procedure 
Infant rats (n = 117) aged 5-13 days were prod- 
ucts of timed-pregnancy Sprague-Dawley-derived 
rats, obtained from Zivic-Miller (Zelionple, PA, 
U.S.A.). Pregnant mothers and pups were housed 
under a 12-h light/dark cycle and fed ad libitum. 
Delivery times were monitored and were accurate 
to within 12 h; day of birth was considered day 0. 
Litters were mixed so that study groups contained 
pups from several litters and were culled to 12 pups. 
Infant rats were subjected to operation 24 h before 
CRH administration and returned to their mothers. 
CRH was always administered between 9:OO and 
10:30 a.m. to minimize diurnal variations in seizure 
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susceptibility (Oliverio et al., 1985) and in endoge- 
nous CRH and GC levels (Watts et al., 1989). 
CRH was administered intracerebroventricularly 
(i,c.v.) through a permanent stainless-steel cannula 
chronically implanted in the lateral ventricle 
(Baram and Schultz, 1991). The stereotaxic coordi- 
nates, using bregma as a landmark were P 0.6, L 
1.8, and V 3.0 in infant rats aged 5-7 days; P 0.6, L 
2, and V 3.3 in pups aged 9-11 days, and P 0.7, L 
2.0, and V 3.3 in rats aged 12-13 days. 
Experimental paradigm 
On the morning of the experiment, infant rats 
were transferred to heated Plexiglas cages. After a 
30-min habituation period, CRH 112-150 X 
rnol or saline was administered i.c.v. in 1 kl by 
microinfusion pump. ACTH (ACTHARGEL, 
RhBne-Poulenc Rorer, Collegeville, PA, U.S.A.) 4 
IU/kg was given intraperitoneally (i.p., 2 kl/g 
weight). In the acute studies, ACTH or vehicle was 
injected 20, 30, or 60 rnin before CRH infusion. In 
the chronic experiments, ACTH (4 IU/kg per dose) 
was given every 6 h for four doses, with the last 
dose given 30 rnin before CRH infusion. 
Experimental groups consisted of CRH alone (n 
= 43), CRH preceded by ACTH (n = 42), ACTH 
alone (n = 20), and salineho drug (n = 12). Litters 
of infant rats were studied at the age of 5 , 6 , 7 , 9 ,  10, 
1 1 ,  or 13 days. Each animal was subjected to ACTH 
or CRH only once. Several groups of animals were 
videotaped, and seizures were scored without 
knowledge of the treatment. In a separate group, 
pups were implanted with bipolar electrodes aimed 
at the amygdala (Baram et al., 1992,1993) to verify 
the epileptiform nature of CRH-induced phenom- 
ena (Baram and Hirsch, 1992) and the effect of 
ACTH. Other groups (n = 4 per age) of rats aged 6 
or 12 days were injected with ACTH or saline and 
killed 30 rnin later for plasma corticosterone 
(CORT) analysis in comparison to noninjected 
pups. CORT was measured by radioimmunoassay 
(RIA) (Baram and Schultz, 1990). 
Scoring and statistical analysis 
We determined time to onset and duration and 
severity of CRH-induced seizures. Pups were 
scored at 5-min intervals for a minimum of 4 h and 
until abnormal behavior subsided. CRH-induced 
seizures were scored as described previously 
(Baram et al., 1992). Automatisms (jaw myoclonus 
and licking) progressed to focal leg clonus and focal 
tonic extension. The most severe manifestations 
consisted of “swimming” seizures that lasted >6 h. 
In pups aged 210 days, CRH resulted in jaw my- 
oclonus followed by “wet-dog shakes,” running, 
and swimming seizures. 
Groups were analyzed for correlation of treat- 
ment with latency, duration, and severity of sei- 
zures. Because no differences were evident be- 
tween acute and chronic ACTH groups, they were 
combined as already described. Significance of dif- 
ferences among groups, for both seizures and 
plasma CORT, were analyzed by Student’s t test 
(STATIT statistics program). The power for differ- 
ences between groups was determined with 
PRIMER biostatistics program, third edition. 
RESULTS 
CRH administration resulted in a prolonged se- 
ries of seizures after a latency of 2-55 min. Rats 
administered vehicle or ACTH alone had no sei- 
zures. There was no difference in time to seizure 
onset (latency) between rats given CRH alone (9.5 
k 1.2 min) and those pretreated with ACTH (12.4 ? 
2.8 min for combined acute and chronic groups) 
(Table 1) .  CRH-induced seizure duration (88.2 ? 9 
vs. 74.7 ? 9.4 min) and severity of seizures were 
also unchanged by ACTH treatment (Table 2). 
Sample size was adequate: The power for a dif- 
ference of 5/6 standard deviation (SD) in latency 
between the entire group of ACTH-treated versus 
the nontreated group was 0.948. For the groups 
aged 5-7 days power (p) for a 1-SD difference in 
latency between groups was 0.84 (Table 1) .  
ACTH administered into the peritoneal space 
reached the circulation in amounts sufficient to 
cause a highly significant increase in plasma CORT 
(Table 3). This increase was evident 30 min after 
injection, at the time CRH was infused. Plasma 
CORT levels for the combined 6- and 12-day-old rat 
groups (n = 8 per group) were 2.47 * 0.24 pg/dl for 
controls, 3.78 -+ 0.54 pg/dl for saline injected, and 
11.83 ? 0.83 pg/dl for rats administered ACTH 
(SEM ? SE). 
DISCUSSION 
ACTH has been used as an anticonvulsant for 
intractable human epilepsy since the early 1950s 
TABLE 1. Latency of CRH-induced seizures 
Age CRH and 
(day) CRH alone (n)’ ACTH (n)a p-Value 
~ ______ 
5-7 11.22 f 1.8 (18) 13.74 * 3.4 (19) 0.264 
9-13 8.45 f 1.6 (20) 11.25 2 4.5 (19) 0.28 
CRH, corticotropin-releasing hormone. 
The power (p) for a difference between groups of 1 SD is 0.84 
for the group aged 5-7 days. For the entire group, the power for 
detection of a difference of 6 rnin (5/6 SD) is 0.948. 
Values are mean * SE. 
a Precise latency was not available for 7 pups aged 5-7 days 
and for 1 pup aged 9-13 days. 
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TABLE 2. Duration of CRH-induced seizures: 
Five-minute epochs 
Age ACTH and 
(day) CRH alone (n)" CRH (ny p-Value 
5-7 19.55 f 2.8 (22) 15.32 f 2.9 (22) 0.14 
9-13 15.95 2 1.6 (20) 15.32 f 2.6 (19) 0.42 
Abbreviation as in Table 1. 
Values are mean f SE. 
" Precise duration was not available for 1 rat aged 9 days. 
(Snead, 1989,1992). It has been used primarily for 
MIS (Sore1 and Dusaucy-Bauloye, 1958), for which 
it is the preferred drug (Aicardi, 1986; Snead, 1990). 
ACTH has proven useful for a variety of other in- 
tractable childhood seizures (Snead, 1992). 
The mechanisms by which ACTH exerts anticon- 
vulsant effects have been a focus of intensive inves- 
tigation (Woodbury, 1952; Urban et al., 1974; 
Holmes and Weber, 1985; Croiset and de Wied, 
1992; Pranzatelli, 1994). ACTH is a neuropeptide 
with both endocrine and neuromodulatory proper- 
ties. The direct effects of ACTH on the CNS have 
been well documented and consist of both behav- 
ioral alterations (de Wied and Ferrari, 1986) and 
electrophysiologic (Urban et al., 1974) and direct 
neuropharmacologic (Pranzatelli, 1994) activities. 
Anticonvulsant properties have been demonstrated 
in immature rodents through use of the kindling par- 
adigm (Holmes and Weber, 1985). These intrinsic 
neuromodulatory actions of ACTH exist in a frag- 
ment (ACTH,,,) devoid of hormonal effects (Ur- 
ban, 1986). This portion of ACTH, however, is in- 
effective for treatment of MIS (Pentella et al., 1982; 
Willig and Lagenstein, 1982). 
The lack of efficacy of ACTH fragments devoid 
of corticotrophic function and the efficacy of gluco- 
corticoids (GC) for MIS suggest that the anticon- 
vulsant potency of ACTH for infants with MIS may 
derive from its hormonal properties (Riikonen, 
1983). GC itself may have intrinsic anticonvulsant 
properties by virtue of direct effects on neuronal 
membrane excitability (McEwen et al., 1991 ; Joels 
and de Kloet, 1992). ACTH may thus be superior to 
prednisone in conventional dose-regimens used for 
MIS by causing sustained higher plasma GC levels 
(Snead et al., 1989). GC, unlike ACTH, readily pen- 
etrate the blood-brain barrier. GC may also act 
through specific receptors to modualte expression 
of several genes in CNS, including those of neuro- 
transmitter or second-messenger systems (McEwen 
et al., 1991). 
An alternative hormonal mechanism of ACTH 
anticonvulsant action is through negative feedback 
suppression of an intrinsic convulsant, CRH 
(Ehlers et al., 1983; Marrosu et al., 1988; Rosen et 
al., 1994), as part of the hypothalamo-pituitary 
adrenal axis (Vale et al., 1981; Jingami et al., 1985). 
CRH exerts excitant properties on a wide variety of 
neurons in several species. In vitro studies of hip- 
pocampal slice preparation (Aldenhoff et al., 1983), 
cerebellar Purkinje neurons (Fox and Gruol, 1993), 
and in vivo electrographic investigations (Ehlers et 
al., 1983; Valentino et al., 1983; Siggins, 1990) am- 
ply document that CRH increases neuronal excit- 
ability. In adult rats, CRH administered i.c.v. re- 
sults in epileptiform discharges in amygdala and 
hippocampus (Marrosu et al., 1988), and 3-7 h later, 
in overt, "limbic" seizures (Ehlers et al., 1983). 
We have recently showed CRH to be a far more 
rapid and potent convulsant when administered to 
infant rats (Baram and Schultz, 1991; Baram et al., 
1992). Seizures occur with a latency of as little as 2 
min and with CRH doses as low as 7.5 x mol 
(as compared with 1,500 X mol in adults). We 
speculated that if ACTH were a direct anticonvul- 
sant,  it should block CRH-induced seizures 
whereas a lack of efficacy would indicate an indi- 
rect hormonal mode of action, though not necessar- 
ily downregulation of CRH synthesis or secretion. 
ACTH was not effective against exogenous CRH- 
induced seizures in the infant rat model in either an 
acute or subacute experimental paradigm. Neither 
latency nor length or severity of CRH-induced sta- 
tus epilepticus was altered. EEG correlates of be- 
havioral seizures (Baram et al., 1992) also were un- 
changed (data not shown). ACTH doses (4 IU/kg 
per dose) were equivalent or higher than those 
shown to be effective in human infants (150 IU/m2/ 
day, 3.5 IU/kg per dose for a typical 7-kg, 0.35-m2 
infant). Furthermore, ACTH reached the circula- 
tion and resulted in significant increase in plasma 
CORT (Table 3). 
Seizures induced by CRH administration in infant 
rats may not provide an optimal model for study of 
ACTH anticonvulsant action in human MIS 
(Baram, 1993). As far as can be extrapolated from 
comparative studies, the full-term human resembles 
a 7-10-day-old rat with regard to brain growth, 
TABLE 3. Plasma corticosterone after ACTH or 
saline injection 
Age (day) Non-injected Saline ACTH 
13.65 f 0.7" 
12 days 2.29 f 0.42 2.68 f 0.43 10.01 +. 0.6" 
Combined: 2.47 * 0.24 3.78 2 0.54 11.83 f 0.8" 
6 days 2.66 t 0.22 4.87 f 0.6 
Four rats per group. Values are Mean f SEM, in kg/dl. Cor- 
ticosterone measured in trunk plasma 30 min after injection. El- 
evation in saline injected pups represents response to stress of 
injection. "p < 0.05. 
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DNA content, and myelinization. A 13-day-old in- 
fant rat is beyond the exponential phase of brain 
growth and may thus be comparable to a 5-10- 
month-old human (Dobbing and Sands, 1973). 
CRH-exposed pups in these experiments may 
therefore be termed “neonatal” (age <10 days) and 
“infant” (age 10-13 days). In rats of both ages, 
these experiments suggest that the mechanism of 
ACTH anticonvulsant efficacy does not involve di- 
rect suppression of CRH-induced enhanced neuro- 
nal excitability. 
CRH administered i.c.v. at the doses used does 
not result in activation of the pituitary and adrenal 
(Baram and Schultz, 1991). Status epilepticus in- 
duced by the peptide is stressful, however, and in- 
creases plasma CORT, presumably through ACTH 
(Baram and Schultz, 1991). This plasma-ACTH in- 
crease probably is insignificant, since the ACTH 
doses used are >104-fold higher than maximal, 
stress-induced ACTH plasma levels in neonatal rats 
(Walker et al., 1991; Yi et al., 1994). 
ACTH does not block the convulsant action of 
exogenous CRH in infant rats. Alternative mecha- 
nisms, such as “hormonally mediated,” feedback 
downregulation of endogenous convulsants, may 
account for the antiepileptic efficacy of ACTH in 
infant brain. 
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